Canaccord Genuity's 46th Annual Growth Conference
Logotype for ASP Isotopes Inc

ASP Isotopes (ASPI) Canaccord Genuity's 46th Annual Growth Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for ASP Isotopes Inc

Canaccord Genuity's 46th Annual Growth Conference summary

12 Aug, 2026

Strategic focus and business structure

  • Operations span electronics, nuclear medicine, and nuclear fuels, with three production facilities in South Africa and recent acquisitions in the U.S.

  • PET Labs is the largest producer of Fluorine-18 radionuclides in South Africa, with expansion plans in the U.S. and Europe.

  • Renergen manages helium and LNG production, with the Virginia Gas Project set to begin helium output by September and a major expansion planned.

  • Quantum Leap Energy is developing nuclear fuel technologies and is being spun out to focus on the nuclear fuel cycle.

  • The company is vertically integrated in stable and radioactive isotope production, enhancing supply chain security and margins.

Technology and production capabilities

  • Utilizes proprietary Aerodynamic Separation Process for gaseous isotopes and Quantum Enrichment (laser-based) for metals.

  • Modular plant design allows flexible scaling and lower capital expenditure compared to traditional centrifuges.

  • Silicon-28 production targets both quantum computing (high purity) and semiconductor (lower purity, higher volume) markets.

  • Helium is critical for semiconductors and medical devices, with supply chain disruptions creating market opportunities.

  • Commercial deliveries for Silicon-28, Carbon-14, and Ytterbium-176 are targeted for the second half of 2026.

Market dynamics and expansion plans

  • Global isotope supply chains are compromised, with most production in Russia; Western customers seek alternatives.

  • PET Labs' revenue growth is driven by investments in production capacity and rising demand for PET and SPECT isotopes.

  • U.S. radiopharmacy acquisitions will be upgraded to produce PET isotopes, with further expansion opportunities identified.

  • Helium market faces shortages due to Middle East disruptions; strategic reserves are depleting, likely driving prices higher.

  • Contracts signed for 15% of phase I helium capacity, with more negotiations ongoing as demand is expected to rise.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more